HighGravityData

Stryker

Guidance from Stryker’s last 8 earnings releases. Every value links to its sentence in the filing. See something wrong? Tell us.
Current guidance
4 items
Releases tracked
8
Latest release
Jul 30, 2026
Data checked
Jul 30, 2026
On this page:Latest changes·Current guidance·Your sector group·History

What changed in the Jul 30, 2026 release

Each item compared with the same item in the previous release (Apr 30, 2026). Values in quotation marks are the company’s words.

New — first stated in this releaseRaised / Lowered / Narrowed / Widened — changed from the prior releaseRevised — wording changed, direction not determinableChanged — value changed; the comparison couldn’t be parsed to a directionReiterated — restated unchangedNot restated — stated before, absent nowRaised and lowered describe the number, not whether the change is favorable.
ChangeMetricPeriodPreviousNowSource
NarrowedOrganic net sales growthfor FY2026“8.0% to 9.5%”“8.3% to 9.3%”Filing ↗
NarrowedAdjusted net earnings per diluted sharefor FY2026“$14.90 to $15.10”“$14.95 to $15.10”Filing ↗
Show 2 items not restated in this release
ChangeMetricPeriodPreviousNowSource
Not restatedForeign exchange impact on sales and adjusted net earnings per diluted sharefor FY2026“slightly positive impact”—Filing ↗
Not restatedSales pricing impactfor FY2026“modestly favorable pricing impact”—Filing ↗

Current guidance

Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.

Current fiscal year
MetricCurrent valuePeriodMeasureFirst statedTimes statedSource
Organic net sales growth“8.3% to 9.3%”for FY2026Company-definedJan 29, 20263Filing ↗
Adjusted net earnings per diluted share“$14.95 to $15.10”for FY2026Company-definedJan 29, 20263Filing ↗
Foreign exchange impact on sales and adjusted net earnings per diluted share“slightly positive impact”for FY2026Company-definedJan 29, 20261Filing ↗
Sales pricing impact“modestly favorable pricing impact”for FY2026Company-definedJan 29, 20261Filing ↗

How one item moved

Adjusted net earnings per diluted share, for FY2025 — every statement across the year, each linked to its filing.

Jan 28, 2025
New
“$13.45 to $13.70”
May 1, 2025
Lowered
“$13.20 to $13.45”
Jul 31, 2025
Raised
“$13.40 to $13.60”
Oct 30, 2025
Narrowed
“$13.50 to $13.60”

How your Medical devices & equipment sector group guides

12 companies in Medical devices & equipment. What they guide on, and who reported this season.

Most-guided metric families
Revenue
9
Organic growth
8
Adjusted EPS
8
Buybacks
6
GAAP EPS
5
Operating margin
4
Dividends
3
Gross margin
2
This season’s releases
MedtronicSep 1, 20263 changes
Becton DickinsonAug 6, 20264 changes
ResMedAug 6, 20260 changes
InsuletAug 5, 202625 changes
Zimmer BiometAug 5, 20263 changes
DexComJul 30, 20263 changes
StrykerJul 30, 20262 changes
Boston ScientificJul 29, 20265 changes
Get this for your own peer set — Peer Guidance Briefing, $3,000.

Full history

Every metric, every release, eight quarters — the complete record as one table.

MetricFY2026FY2025FY2024No period
Net sales——1 statement—
Net sales impact from foreign exchange—1 statement——
Organic net sales growth3 statements4 statements1 statement—
Adjusted net earnings per diluted share3 statements4 statements1 statement1 statement
Adjusted net earnings per diluted share impact from foreign exchange—1 statement——
The full record for Stryker and its Medical devices & equipment peers, delivered as a Peer Guidance Briefing — PDF and Excel, every value linked to its filing.

Filings

The 8 earnings releases this page is built from.

FiledFiscal periodAccessionGuidance items
Jul 30, 2026FY2026 Q20000310764-26-0000482Open filing ↗
Apr 30, 2026FY2026 Q10000310764-26-0000252Open filing ↗
Jan 29, 2026FY2025 Q40000310764-26-0000064Open filing ↗
Oct 30, 2025FY2025 Q30000310764-25-0001262Open filing ↗
Jul 31, 2025FY2025 Q20000310764-25-0001033Open filing ↗
May 1, 2025FY2025 Q10000310764-25-0000723Open filing ↗
Jan 28, 2025FY2024 Q40000310764-25-00000511Open filing ↗
Oct 29, 2024FY2024 Q30000310764-24-0001134Open filing ↗
Values in quotation marks are the company’s words; the classification and filing links are HighGravityData’s. HighGravityData does not score or rank companies or give investment advice.
Report an error